The liver is the commonest site of metastatic disease for patients with colorectal cancer, with
at least 25% developing colorectal liver metastases (CRLM) during the course of their …

Neuroendocrine tumors from gastro-pancreatic origin (GEP-NET) can be responsible for
liver metastases. Such metastases can be the dominant part of the disease as well due to …

Purpose SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and
safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin …

Purpose Liver dissemination is a major cause of mortality among patients with advanced
colorectal cancer. Hepatic intra-arterial injection of the β-emitting isotope yttrium-90 (90Y) …

Radioembolization (RE)‐induced liver disease (REILD) has been defined as jaundice and
ascites appearing 1 to 2 months after RE in the absence of tumor progression or bile duct …

Purpose This study was designed to evaluate overall survival after radioembolization or best
supportive care (BSC) in patients with chemotherapy-refractory liver-dominant metastatic …

Metastatic liver disease is the most common cause of death in cancer patients. Complete
surgical resection is currently considered the only curative treatment, with only about 25% of …

Radioembolization (RE) is a relatively novel treatment modality for primary and secondary
hepatic malignancies. Microspheres embedded with a β-emitting radioisotope are injected …

Introduction The management of unresectable, chemorefractory colorectal cancer liver
metastases (CRCLM) is a clinical dilemma. Yttrium-90 (Y90) radioembolization is a …

Unresectable primary and metastatic liver tumors are a leading cause of cancer mortality
and morbidity. This remains a challenging and key task for every oncologist despite …